Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Papadopoulou

Showing results (1-10 of 72) with videos related to

Pageof 8
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2003
NLCQ-1 (NSC 709257): exploiting hypoxia with a weak DNA-intercalating bioreductive drugMaria V Papadopoulou, William D Bloomer
In Vivo (Athens, Greece)|July 10, 2008
NLNQ-1, a 2-[3-(2-nitro-1-imidazolyl) propylamino]-3-chloro-1,4-naphthoquinone, as a hypoxia-selective cytotoxin and radiosensitizerMaria V Papadopoulou, William D Bloomer
In Vivo (Athens, Greece)|April 18, 2007
DNA repair mechanisms are involved in the hypoxia-dependent toxicity of NLCQ-1 (NSC 709257) and its synergistic interaction with alkylating agentsMaria V Papadopoulou, William D Bloomer
Anti-Cancer Drugs|May 12, 2009
Nitroimidazole-based bioreductive compounds bearing a quinazoline or a naphthyridine chromophoreMaria V Papadopoulou, William D Bloomer
Anticancer Research|September 15, 2005
Mechanisms involved in the potentiation of paclitaxel or 5-fU by the hypoxic cytotoxin NLCQ-1 (NSC 709257) in vitroMaria V Papadopoulou, Xinhai Ji, William D Bloomer
Acta Ophthalmologica Scandinavica|February 13, 2001
Retinoblastoma with an unusual presentation in a child with polydactyly. Clinical associations and genetic implicationsI Tsinopoulos, V Papadopoulou, A Papandroudis, et al.
European Journal of Applied Physiology|February 27, 2015
Heart rate variability and critical flicker fusion frequency changes during and after parachute jumping in experienced skydiversM Cavalade, V Papadopoulou, S Theunissen, et al.
Cancer Chemotherapy and Pharmacology|September 20, 2001
Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in miceM V Papadopoulou, M Ji, W D Bloomer
Oncology Research|August 31, 2002
Synergistic enhancement of the antitumor effect of taxol by the bioreductive compound NLCQ-1, in vivo: comparison with tirapazamineMaria V Papadopoulou, Ming Ji, William D Bloomer
Oncology Research|August 6, 2003
Synergistic interaction between cyclophosphamide or paclitaxel and the bioreductive compound NLCPQ-1, in vivoM V Papadopoulou, M Ji, W D Bloomer
Pageof 8

Showing results (1-10 of 72) with videos related to

Sort By:
Pageof 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2003
NLCQ-1 (NSC 709257): exploiting hypoxia with a weak DNA-intercalating bioreductive drugMaria V Papadopoulou, William D Bloomer
In Vivo (Athens, Greece)|July 10, 2008
NLNQ-1, a 2-[3-(2-nitro-1-imidazolyl) propylamino]-3-chloro-1,4-naphthoquinone, as a hypoxia-selective cytotoxin and radiosensitizerMaria V Papadopoulou, William D Bloomer
In Vivo (Athens, Greece)|April 18, 2007
DNA repair mechanisms are involved in the hypoxia-dependent toxicity of NLCQ-1 (NSC 709257) and its synergistic interaction with alkylating agentsMaria V Papadopoulou, William D Bloomer
Anti-Cancer Drugs|May 12, 2009
Nitroimidazole-based bioreductive compounds bearing a quinazoline or a naphthyridine chromophoreMaria V Papadopoulou, William D Bloomer
Anticancer Research|September 15, 2005
Mechanisms involved in the potentiation of paclitaxel or 5-fU by the hypoxic cytotoxin NLCQ-1 (NSC 709257) in vitroMaria V Papadopoulou, Xinhai Ji, William D Bloomer
Acta Ophthalmologica Scandinavica|February 13, 2001
Retinoblastoma with an unusual presentation in a child with polydactyly. Clinical associations and genetic implicationsI Tsinopoulos, V Papadopoulou, A Papandroudis, et al.
European Journal of Applied Physiology|February 27, 2015
Heart rate variability and critical flicker fusion frequency changes during and after parachute jumping in experienced skydiversM Cavalade, V Papadopoulou, S Theunissen, et al.
Cancer Chemotherapy and Pharmacology|September 20, 2001
Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in miceM V Papadopoulou, M Ji, W D Bloomer
Oncology Research|August 31, 2002
Synergistic enhancement of the antitumor effect of taxol by the bioreductive compound NLCQ-1, in vivo: comparison with tirapazamineMaria V Papadopoulou, Ming Ji, William D Bloomer
Oncology Research|August 6, 2003
Synergistic interaction between cyclophosphamide or paclitaxel and the bioreductive compound NLCPQ-1, in vivoM V Papadopoulou, M Ji, W D Bloomer
Pageof 8